Loading
DAN-311 is an experimental targeted high-capacity drug conjugate from Dantari, in preclinical development for HER2-positive breast cancer and HER2-low breast cancer; its current status is not stated.
DAN-311 is a targeted high-capacity drug conjugate from Dantari. A drug conjugate on the T-HDC platform for HER2-positive and HER2-low breast cancer. Its furthest stage is preclinical development, for HER2-positive breast cancer and HER2-low breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Planned to enter the clinic in late 2023 (Dec 2022 coverage); no registry study names DAN-311. It has not been shown to work in people.
A drug conjugate on the T-HDC platform for HER2-positive and HER2-low breast cancer.
1.DAN-311's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DAN-311" OR ABSTRACT:"DAN-311") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DAN-311, not a curated reading list.
Shares Dantari and the tag pipeline.
Shares Dantari and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/